simvastatin has been researched along with Arteriosclerosis, Coronary in 202 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (12.38) | 18.2507 |
| 2000's | 121 (59.90) | 29.6817 |
| 2010's | 53 (26.24) | 24.3611 |
| 2020's | 3 (1.49) | 2.80 |
| Authors | Studies |
|---|---|
| Goel, A; Lavezo, J; Podboy, A; Wong, K | 1 |
| Al-Rashid, F; Dykun, I; Hendricks, S; Jánosi, RA; Mahabadi, AA; Rassaf, T; Totzeck, M; Wiefhoff, D | 1 |
| Bonsu, KO; Buabeng, KO; Kadirvelu, A; Owusu, IK; Reidpath, DD | 1 |
| Çoban, N; Erginel-Ünaltuna, N; Güleç, Ç; Özsait Selçuk, B | 1 |
| Barter, PJ | 1 |
| Buranasupkajorn, P; Buse, JB; Doria, A; Gao, H; Gerstein, HC; Hastings, T; Kraft, P; Marcovina, SM; Mendonca, C; Morieri, ML; Motsinger-Reif, AA; Mychaleckyj, JC; Parè, G; Pigeyre, M; Rotroff, DM; Shah, HS; Sigal, RJ; Sjaarda, J; Wagner, MJ | 1 |
| Gao, Z; Jiang, H; Lu, X; Ruan, Z; Wang, Z; Wu, B; Ye, X | 1 |
| Boden, WE; Hartigan, PM; Maron, DJ; Neff, DR; Weintraub, WS | 1 |
| Campos, AH; Fernandes, JL; Katz, M; Marti, L; Parra, PR; Pesaro, AE; Serrano, CV | 1 |
| Kang, S; Liu, XB; Liu, Y | 1 |
| Gao, C; Li, M; Xiao, W; Xu, W; Yu, J | 1 |
| Kaznacheeva, EI; Kheĭmets, GI; Kukharchuk, VV; Liakishev, AA; Miklishanskaia, SV; Vlasik, TN | 1 |
| Berthold, HK; Ekroos, K; Gouni-Berthold, I; Hurme, R; Kauhanen, D; Kleber, ME; Laaksonen, R; März, W; Suoniemi, M; Sylvänne, T; Tarasov, K | 1 |
| Che, W; Liu, B; Wang, H; Yan, H; Zhu, W | 1 |
| Cho, DY; Hong, JH; Hyeon, SH; Kim, CJ; Kim, EY; Kim, H; Kim, SW; Kim, TH; Kwon, JE; Lee, WS; Mintz, GS; Senguttuvan, NB; Seo, JS; Seok, JW; Weissman, NJ | 1 |
| Cui, W; Du, H; Hao, J; Hu, H; Yang, J; Zheng, H | 1 |
| Kowalska, B; Krysiak, R; Okopień, B; Żmuda, W | 1 |
| Choi, YH; Hellmich, M; Krause, P; Kuhn, EW; Kuhr, K; Liakopoulos, OJ; Reuter, H; Thurat, M; Wahlers, T | 1 |
| Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM | 1 |
| Cipollone, F; Creemers, EE; de Ronde, MW; Halliani, A; Kok, MG; Mandolini, C; Meijers, JC; Moerland, PD; Nieuwland, R; Pinto-Sietsma, SJ; Sondermeijer, BM | 1 |
| Gitt, AK; Hildemann, SK; Jannowitz, C; Karmann, B; Pittrow, D; Schaefer, JR; Sonntag, F; Weizel, A | 1 |
| Amrein, K; Binder, J; Cvirn, G; Ferstl, U; Froehlich, H; Hallström, S; Hörl, G; Jürgens, G; Koidl, C; Ledinski, G; Scharnagl, H; Stojakovic, T; Tafeit, E; Trauner, M | 1 |
| Januszek, R | 2 |
| Albers, JJ; Fleg, JL; Marcovina, SM; O'Brien, KD; Slee, A | 1 |
| Cheng, CF; Liu, F; Tan, Y; Wang, YA; Yang, L; Yu, XJ; Zhou, MH | 1 |
| Besseling, J; Hovingh, GK; Huijgen, R; Hutten, BA; Kastelein, JJP | 1 |
| Ardanaz, E; Arriola, L; Balkau, B; Barroso, I; Boeing, H; Burgess, S; Deloukas, P; Forouhi, NG; Franks, PW; Grioni, S; Kaaks, R; Key, TJ; Langenberg, C; Lotta, LA; Luan, J; McCarthy, MI; Navarro, C; Nilsson, PM; O'Rahilly, S; Overvad, K; Palli, D; Panico, S; Perry, JRB; Quirós, JR; Riboli, E; Rolandsson, O; Sacerdote, C; Salamanca, EC; Sattar, N; Savage, DB; Scott, RA; Sharp, SJ; Slimani, N; Spijkerman, AM; Stewart, ID; Tjonneland, A; Tumino, R; van der A, DL; van der Schouw, YT; Wareham, NJ; Willems, SM | 1 |
| Heidenreich, PA; Knowles, JW; Lin, S; Maron, DJ; Rodriguez, F; Virani, SS | 1 |
| Barbieri, L; Bellomo, G; Daffara, V; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Al-Tamimi, O; Bakir, S; Bazargani, N; Binbrek, A; Gopal, R; Shakir, DK; Zubaid, M | 1 |
| Einecke, D | 2 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Abdel-Wahab, M; Geist, V; Herrmann, L; Khattab, AA; Liska, B; Richardt, G; Tölg, R; Westphal, R | 1 |
| Baker, AB; Beigel, R; Chatzizisis, YS; Coskun, AU; Daley, W; Edelman, ER; Feldman, CL; Gerrity, RG; Jonas, M; Maynard, C; Stone, BV; Stone, PH | 1 |
| Fee, WH | 1 |
| Porat, G | 1 |
| Gandhi, MJ | 1 |
| de Lemos, JA; Gomes, F; Monteiro, HP; Nicolau, JC; Pesaro, AE; Rached, F; Ribeiro, AF; Segre, CA; Serrano, CV; Yoshida, VM | 1 |
| Böhm, F; Hjemdahl, P; Malmström, RE; Pernow, J; Settergren, M | 1 |
| Averna, M; Brudi, P; Farnier, M; Johnson-Levonas, AO; Massaad, R; Missault, L; Vandormael, K; Vaverkova, H; Viigimaa, M | 1 |
| Abletshauser, C; Geisen, U; Hoffmann, MM; Odünc, N; Pütz, G; Schäfer, G; Schewe, T; Siegel, E; Winkler, K | 1 |
| Hjemdahl, P; Jørgensen, L; Malmström, RE; Ostergren, J | 1 |
| Böhm, F; Kalani, M; Pernow, J; Rydén, L; Settergren, M | 1 |
| Hong, MK; Kang, DH; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, JK | 1 |
| McDaniel, MC; Samady, H | 1 |
| Itakura, H; Kita, T; Mabuchi, H; Matsuzaki, M; Matsuzawa, Y; Nakaya, N; Oikawa, S; Saito, Y; Sasaki, J; Shimamoto, K | 1 |
| Chan, HT; Dai, YL; Fong, B; Lau, CP; Lee, SW; Li, SW; Luk, TH; Siu, CW; Tam, S; Tse, HF; Yiu, KH | 1 |
| Carabello, BA | 1 |
| Biesenbach, P; Gremmel, T; Hörl, WH; Kain, R; Säemann, MD | 1 |
| Drexel, H; Rein, P; Saely, CH | 1 |
| Breuer, HW | 1 |
| Fang, YQ; Fu, CJ; He, DF; Shi, WB; Wang, HY; Wang, XK; Yang, CM; Zeng, CY; Zhang, Y | 1 |
| Hong, MK; Kim, BK | 1 |
| Ahn, Y; Cho, JG; Choi, YH; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Ma, EH; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, NS; Youn, HJ | 1 |
| Chockalingam, A; Kar, S | 1 |
| Campos, AH; Cavalcanti, AB; de Lemos, JA; Fernandes, JL; Maranhão, RC; Martins, HS; Nicolau, JC; Pesaro, AE; Serrano, CV; Souza, HP | 1 |
| Budinski, D; Eriksson, M; Hounslow, N | 1 |
| Karska-Basta, I; Kubicka-Trząska, A; Romanowska-Dixon, B; Undas, A | 1 |
| Bakris, G; de Guzman, E; Lazich, I; Oliva, R; Patel, A; Sarafidis, P | 1 |
| Liu, KS; Wang, HH; Wong, MC | 1 |
| Baek, SD; Jang, SJ; Kim, TH; Lee, HS; Leem, J; Ok, TJ; Park, SE; Park, SJ | 1 |
| Chapman, MJ | 1 |
| Garcia-Garcia, HM; Okamura, T; Serruys, PW; Shin, ES | 1 |
| Ockene, IS | 1 |
| Armitage, J; Clarke, R; Collins, R; Hill, MR; Hopewell, JC; Offer, A; Otvos, JD; Parish, S | 1 |
| Chuck, AW; Jacobs, P; Ohinmaa, A; Thanh, NX | 1 |
| Kuller, LH; Mackey, RH | 1 |
| Armitage, J; Chen, F; Chen, YP; Chen, ZM; Feng, F; Gao, Y; Hopewell, JC; Hundei, WB; Jiang, LX; Landray, M; Li, J; Li, X; Liu, JM; Valdes-Marquez, E; Zhang, D; Zhang, HB | 1 |
| An, K; Cui, Z; Sun, Y; Wu, Y; Xu, L; Yuan, H | 1 |
| Gylling, H; Miettinen, TA | 1 |
| Dirschinger, J; Holle, H; Hösl, K; Kastrati, A; Kastrati, D; Mehilli, J; Neumann, FJ; Pache, J; Schömig, A; Seyfarth, M | 1 |
| Roberts, WC | 1 |
| Ahn, JY; Choi, IS; Choi, YM; Jeong, EM; Jin, DK; Kim, DS; Kim, HS; Koh, KK; Park, GS; Shin, EK; Son, JW | 1 |
| Liao, JK | 1 |
| Christophersen, B; Falch, D; Gullestad, L; Lund, TM; Skårdal, R; Torsvik, H | 1 |
| Conroy, C; Robinson, JG; Wickemeyer, WJ | 1 |
| Kulbertus, H; Scheen, AJ | 1 |
| Gratsiansky, NA | 1 |
| Aukrust, P; Frøland, SS; Gullestad, L; Kastelein, JJ; Pedersen, TR; Semb, AG; Smilde, T; Stalenhoef, AF; Tripp, MD; Ueland, T; van Wissen, S; Waehre, T | 1 |
| Brown, BG; Giovanni, A; Lichtenstein, AH; Matthan, NR; Schaefer, EJ | 1 |
| Brady, TJ; Derfler, K; Haas, M; Hoffmann, U; Kostner, K; Stadler, A | 1 |
| Buller, CE; Burton, JR; Catellier, D; Dzavik, V; Montague, TJ; Plante, S; Taylor, D; Teo, KK; Tymchak, W | 1 |
| Arnesen, KE; Aukrust, P; Damås, JK; Frøland, SS; Gullestad, L; Holm, AM; Pedersen, TR; Semb, AG; Torsvik, H; Waehre, T | 1 |
| Fonarow, GC | 1 |
| Alkhenizan, A | 1 |
| Aronow, WS | 1 |
| Origasa, H; Yokoyama, M | 1 |
| Mishra, TK; Routray, S | 1 |
| Flevari, P; Koniavitou, K; Kremastinos, DT; Kroupis, C; Kyriakides, ZS; Sbarouni, E | 1 |
| Cabezas, MC; De Jaegere, PP; Erkelens, DW; Halkes, CJ; Plokker, HW; van Wijk, JP | 1 |
| Antonini-Canterin, F; Cervesato, E; Granata, G; Nicolosi, GL; Pavan, D; Piazza, R; Popescu, BA; Zuppiroli, A | 1 |
| Aicher, A; Badorff, C; Dimmeler, S; Fichtlscherer, S; Koyanagi, M; Rupp, S; Urbich, C; Zeiher, AM | 1 |
| Beere, PA; Clearfield, M; Girman, CJ; Gotto, AM; Kjekshus, J; Mercuri, M; Pedersen, TR; Pyörälä, K; Rhodes, T | 1 |
| Albers, JJ; Brown, BG; Chait, A; DeAngelis, D; Dowdy, AA; Frohlich, J; Heise, N; Morse, JS; Zhao, XQ | 1 |
| Fang, CH; Li, JJ | 1 |
| Aukrust, P; Damås, JK; Frøland, SS; Gullestad, L; Haug, T; Semb, AG; Smith, C; Tunheim, SH; Waehre, T; Yndestad, A | 1 |
| Mancini, D; Pinney, SP | 1 |
| Bonow, RO; Gheorghiade, M; Kim, RJ; Klein, L; Stone, NJ | 1 |
| Andreassen, AK; Aukrust, P; Gullestad, L; Hognestad, A; Holm, T; Kjekshus, JK; Semb, AG; Stokke, O; Wergeland, R | 1 |
| Duncan, E; Nageh, T; Thomas, MR | 1 |
| Haghfelt, T; Jensen, LO; Pedersen, KE; Stender, S; Thayssen, P | 1 |
| Hosoda, S; Kaburagi, T; Kitabatake, A; Mizuno, K; Nakamura, H; Ohashi, Y; Tochihara, T | 1 |
| Bilchick, KC; Blumenthal, RS; Henrikson, CA; Kasper, EK; Skojec, D | 1 |
| Bilheimer, D; Chung, N; Davies, MJ; Lee, K; Loeys, T; Morales, D; Sangwatanaroj, S; Shah, A; Yin, WH; Zhu, JR | 1 |
| Ahn, JY; Ahn, TH; Choi, IS; Han, SH; Jeong, EM; Jin, DK; Kim, HS; Koh, KK; Shin, EK | 1 |
| Ahn, JY; Chung, WJ; Han, SH; Jin, DK; Kim, DS; Kim, HS; Koh, KK; Park, GS; Shin, EK; Son, JW | 1 |
| Gawaz, M; Gorchakova, O; Joost, A; Kastrati, A; Mocz, A; Schömig, A; von Beckerath, N | 1 |
| Buirma, R; Castro Cabezas, M; De Jaegere, PP; Halkes, CJ; Plokker, HW; van der Helm, YJ; van Tol, A; van Wijk, JP | 1 |
| Carneiro, RC; Cunha, AB; Romêo Filho, LJ; Tessarolo, LE; Verri, V | 1 |
| Sawicki, PT; Weizel, A | 1 |
| Judge, HM; Peters, G; Smith, SM; Storey, RF | 1 |
| Kremastinos, DT; Kyriakides, ZS; Sbarouni, E | 1 |
| Bachutashvili, Z; Chapidze, G; Dolidze, N; Kapanadze, S; Latsabidze, N | 1 |
| Reasner, CA | 1 |
| Bhatt, DL; Karha, J | 1 |
| Amoroso, G; Ciabatti, N; De Carlo, M; Limbruno, U; Mariani, M; Micheli, A; Papini, B; Petronio, AS | 1 |
| Anderson, D; Bula, RL; Gulaya, V; Lankford, B; Lapu-Bula, R; Oduwole, A; Ofili, E; Pemu, PI | 1 |
| Beanlands, R; deKemp, RA; Duchesne, L; Higginson, L; Ling, MC; McPherson, R; Ruddy, TD; Ukkonen, H; Williams, KA | 1 |
| McKenney, JM | 1 |
| Celinska-Löwenhoff, M; Domagala, TB; Dropinski, J; Iwaniec, T; Löwenhoff, T; Szczeklik, A; Undas, A | 1 |
| Gotto, AM | 1 |
| Meiser, B; Reichart, B; Thiery, J; Wenke, K | 1 |
| Bellasi, A; Raggi, P | 1 |
| Forslid, A; Kornerup-Hansen, A; Kovanen, P; Liuba, P; Paakkari, I; Pentikäinen, M; Persson, K; Pesonen, E; Østergård, G | 1 |
| Aukrust, P; Boullier, A; Damås, JK; Green, S; Quehenberger, O; Sandberg, WJ; Smith, C; Waehre, T | 1 |
| Ovbiagele, B | 1 |
| Haghfelt, T; Jensen, LO; Pedersen, KE; Thayssen, P | 1 |
| Rosenson, RS | 1 |
| Evans, T; Friend, A; Kamalesh, M; Rao, R; Sawada, S; Schellhase, E | 1 |
| Celinska-Löwenhoff, M; Löwenhoff, T; Szczeklik, A; Undas, A | 1 |
| Carlier, SG; Haghfelt, T; Jensen, LO; Mintz, GS; Pedersen, KE; Thayssen, P | 1 |
| Kakizoe, H; Sadamatsu, K; Seto, T; Shimokawa, H; Tashiro, H; Yamamoto, K | 1 |
| Budzyński, J; Fabisiak, J; Pułkowski, G; Suppan, K; Swiatkowski, M | 1 |
| Cheong, SS; Han, KH; Hong, MK; Jang, JS; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, CB; Park, DW; Park, SJ; Park, SW | 1 |
| Gennimata, V; Ikonomidis, I; Kotsis, V; Lekakis, J; Pitiriga, V; Protogerou, A; Zakopoulos, N | 1 |
| Bakhutashvili, ZV; Dolidze, NK; Kapanadze, SD; Latsabidze, NE | 1 |
| Auteri, A; Bruni, F; Ciani, F; Ghezzi, A; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Pontani, A; Puccetti, L | 1 |
| Bergler, A; Czepluch, FS; Waltenberger, J | 1 |
| Gratsianskiĭ, NA; Masenko, VP; Smetanina, IN; Vaulin, NA | 1 |
| Gans, RO; May, JF; Mulder, DJ; Smit, AJ; Tervaert, JW; van Doormaal, JJ; van Haelst, PL; Wobbes, MH; Zijlstra, F | 1 |
| Beresewicz, A; Duda, M; Kiliszek, M; Maczewski, M; Opolski, G; Styczyński, G | 1 |
| Celińska-Löwenhoff, M; Gluszko, P; Löwenhoff, T; Undas, A | 1 |
| Akbulut, M; Balin, M; Baydas, A; Kayancicek, H; Korkmaz, H; Ozbay, Y | 1 |
| Kaul, P | 1 |
| Azzellino, A; Balestri, G; Cazzaniga, M; Cerrito, MG; Cusa, EN; DeCarlini, C; Ferrari, AU; Garducci, S; Guerra, L; Lavitrano, ML; Loardi, C; Mancia, G; Menicanti, L; Paolini, G; Radaelli, A; Santo, D | 1 |
| Chello, M; Coccia, R; Covino, E; Foppoli, C; Lusini, M; Perluigi, M; Spadaccio, C | 1 |
| Federman, DG | 1 |
| Chen, H; Liu, X; Luo, Y; Ren, JY; Wang, RJ; Wu, P; Xing, Y; Zhang, WL | 1 |
| Chen, JW; Chen, YH; Huang, SL; Leu, HB; Lin, CP; Lin, WT; Liu, TZ | 1 |
| Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, AH; Roeters van Lennep, HW; Zwinderman, AH | 1 |
| Aukrust, P; Breland, UM; Damås, JK; Fevang, B; Frøland, SS; Gullestad, L; Halvorsen, B; Oie, E; Otterdal, K; Sandberg, WJ; Smith, C; Waehre, T; Yndestad, A | 1 |
| Castiglioni, L; Cosentino, M; Ferrari, M; Gaudio, G; Grandi, AM; Guasti, L; Klersy, C; Lecchini, S; Maio, RC; Marino, F; Rasini, E; Venco, A | 1 |
| Liew, TV; Ray, KK | 1 |
| Abrahamson, D; Detrano, RC; Franklin, SS; Henein, N; Kashyap, ML; Kukes, G; Rosenzweig, B; Teng, W; Willner, R; Wong, ND | 1 |
| Stehbens, WE | 1 |
| Kulbertus, H; Legrand, V; Martinez, C | 1 |
| Davies, G; Kitano, Y; Maher, VM; Matthews, S; Mir, A; Neuwirth, C; Prescott, RJ; Rees, A; Shortt, MB; Thompson, GR | 1 |
| Aengevaeren, WR; Bruschke, AV; Kroon, AA; Reiber, JH; Stalenhoef, AF; Uijen, GJ; van der Werf, T | 1 |
| Bateman, TM; Conn, RD; Lavie, CJ; O'Keefe, JH | 1 |
| Rackley, CE | 1 |
| Pederson, JP; Weintraub, WS | 1 |
| Aengevaeren, WR; Kroon, AA; Stalenhoef, AF; Uijen, GJ; van der Werf, T | 1 |
| Kroon, AA; Stalenhoef, AF; van Asten, WN | 1 |
| Buller, C; Burton, JR; Montague, TJ; Plante, S; Teo, KK; Yokoyama, S | 1 |
| Emura, S; Fukuoka, M; Kato, H; Kawazoye, S; Kishikawa, H; Ohmori, K; Okada, R; Oogushi, K; Takashima, T | 1 |
| Kesäniemi, YA | 1 |
| Albers, J; Brown, BG; Chait, A; Cheung, M; DeAngelis, D; Dowdy, A; Fisher, LD; Frohlich, J; Heise, N; Zhao, XQ | 1 |
| Mabuchi, H | 1 |
| Hasnain, S; McLay, JS; Webster, J | 1 |
| Baller, D; Betker, S; Gleichmann, U; Holzinger, J; Lehmann, J; Montanus, H; Notohamiprodjo, G; Weise, R | 1 |
| Baller, D; Gleichmann, U; Holzinger, J; Lehmann, J; Notohamiprodjo, G; Weise, R | 1 |
| Kostner, KM | 1 |
| Pedersen, TR | 1 |
| Berg, K; Cook, TJ; Faergeman, O; Haghfelt, T; Kjekshus, J; Kristianson, J; Miettinen, T; Olsson, AG; Pedersen, TR; Pyörälä, K; Strandberg, TE; Thorgeirsson, G; Troedsson, L; Wedel, H; Wilhelmsen, L | 1 |
| Brown, WV | 1 |
| Buller, CE; Burton, JR; Catellier, D; Dzavik, V; Montague, TJ; Plante, S; Taylor, D; Teo, KK; Tymchak, W; Yokoyama, S | 1 |
| Chik, G; Crook, MA; Lumb, PJ; Wierzbicki, AS | 1 |
| Vita, JA; Winniford, M; Yeung, AC | 1 |
| Maeda, K; Minami, M; Yasunari, K; Yoshikawa, J | 1 |
| Ahn, JY; Choi, IS; Choi, YM; Jin, DK; Koh, KK; Park, GS; Shin, EK; Sohn, MS; Son, JW | 1 |
| Castro Cabezas, M; de Jaegere, PP; Erkelens, DW; Halkes, CJ; Plokker, HW; van Der Helm, Y; van Dijk, H | 1 |
| Kris-Etherton, PM | 1 |
| Christenson, JT | 1 |
| Adachi, M; Hirano, T; Katagiri, T; Koba, S; Sakai, K; Sakaue, T; Yoshino, G | 1 |
| SoRelle, R | 1 |
| Altamura, L; Chiariello, L; Crea, F; Gaspardone, A; Gioffrè, PA; Proietti, I; Tomai, F; Versaci, F | 1 |
| Giri, S; Moyna, NM; Thompson, PD; Waters, DD; Weber, KM; White, CM | 1 |
| Ahmad, U; Ertel, N; Li, W; Morris, MT; Williams, ML; Yousseff, M | 1 |
| Böhm, M; Hamm, CW; Heeschen, C; Laufs, U; Snapinn, S; White, HD | 1 |
| de Boer, A; Fishman, PA; Heckbert, SR; Klungel, OH; Leufkens, HG; Psaty, BM; Sullivan, SD; Veenstra, DL | 1 |
| Drown, DJ | 1 |
| Tsao, P; Yeung, AC | 1 |
| Oliver, MF | 1 |
| Walker, JF | 1 |
| Oogushi, K | 1 |
| Barlow, CW; Friedman, BM; Myburgh, DP; Smith, DH; Soicher, ER; Steenkamp, WF | 1 |
23 review(s) available for simvastatin and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Registries; Saphenous Vein; Simvastatin; Treatment Outcome; Young Adult | 2013 |
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily G, Member 5; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Genetic Association Studies; Genetic Variation; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Odds Ratio; Polymorphism, Genetic; Proprotein Convertase 9; Receptors, LDL; Risk; Simvastatin | 2016 |
Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management considerations.
Topics: Acute Kidney Injury; Aged, 80 and over; Coronary Artery Disease; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Myocardial Infarction; Renal Dialysis; Rhabdomyolysis; Simvastatin | 2013 |
Pitavastatin: novel effects on lipid parameters.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Europe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Russia; Simvastatin; Triglycerides | 2011 |
Benefits of pharmaceutical innovation: the case of simvastatin in Canada.
Topics: Adolescent; Adult; Anticholesteremic Agents; Canada; Coronary Artery Disease; Diffusion of Innovation; Drug Industry; Female; Health Care Costs; Humans; Male; Middle Aged; Public Health; Simvastatin; Survival Analysis; Young Adult | 2012 |
Beyond lipid lowering: the role of statins in vascular protection.
Topics: Animals; Cardiovascular Diseases; Coronary Artery Disease; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neovascularization, Physiologic; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin; Stroke | 2002 |
Aggressive treatment of atherosclerosis: the time is now.
Topics: Aspirin; Coronary Artery Disease; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Factors; Simvastatin | 2003 |
Hypercholesterolemia. The evidence supports use of statins.
Topics: Aged; Cholesterol, HDL; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metabolic Syndrome; Pravastatin; Simvastatin | 2003 |
Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment.
Topics: Anticholesteremic Agents; Coronary Artery Disease; Coronary Vessels; Echocardiography; Everolimus; Heart Transplantation; Humans; Immunosuppressive Agents; Reoperation; Risk Factors; Simvastatin; Sirolimus; Transplantation, Homologous; Ultrasonography, Interventional | 2004 |
Treatment of hyperlipidemia in cardiac transplant recipients.
Topics: Algorithms; Coronary Artery Disease; Endothelium, Vascular; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Pravastatin; Simvastatin | 2004 |
Commentary: A new approach to atherogenic dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Niacin; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 2005 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.
Topics: Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2005 |
[Atherosclerosis imaging to assess plaque progression].
Topics: Adult; Aged; Animals; Aortic Diseases; Arteriosclerosis; Calcinosis; Cardiovascular Diseases; Carotid Artery Diseases; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Disease; Cost-Benefit Analysis; Disease Progression; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Magnetic Resonance Imaging; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Time Factors; Tomography, X-Ray Computed | 2005 |
Intensive statin therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Atorvastatin; Blood Platelets; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 2008 |
The new paradigm for coronary artery disease: altering risk factors, atherosclerotic plaques, and clinical prognosis.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antioxidants; Coronary Angiography; Coronary Artery Disease; Endothelium, Vascular; Exercise Test; Humans; Hypercholesterolemia; Inflammation; Lovastatin; Platelet Aggregation Inhibitors; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 1996 |
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Topics: Carotid Artery Diseases; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Serum triglycerides and clinical benefit in lipid-lowering trials.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Myocardial Revascularization; Niacin; Simvastatin; Treatment Outcome; Vitamins | 1998 |
[Hyperlipidemia and arteriosclerosis].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Pravastatin; Simvastatin | 1998 |
[Aggressive therapy and combination therapy in severe hyperlipidemia].
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 1999 |
Statin trials and goals of cholesterol-lowering therapy after AMI.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Europe; Humans; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; United States | 1999 |
Cholesterol lowering in atherosclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin | 2000 |
82 trial(s) available for simvastatin and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fenofibrate; Genetic Association Studies; Genetic Markers; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Polymorphism, Single Nucleotide; Risk Assessment; Risk Factors; Simvastatin | 2018 |
Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial).
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Revascularization; Retrospective Studies; Secondary Prevention; Simvastatin; Treatment Outcome | 2013 |
Increasing doses of simvastatin versus combined ezetimibe/simvastatin: effect on circulating endothelial progenitor cells.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Combinations; Endothelial Cells; Ezetimibe, Simvastatin Drug Combination; Female; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Stem Cells | 2013 |
[Influence of intensive hypolipidemic therapy on blood concentration of lipoprotein-associated phospholipase A2 in patients with ischemic heart disease].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Ezetimibe; Female; Humans; Lipid Metabolism; Male; Middle Aged; Severity of Illness Index; Simvastatin; Treatment Outcome | 2013 |
Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Azetidines; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; rho-Associated Kinases; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Vascular Stiffness | 2013 |
The effect of ezetimibe-statin combination on steroid hormone production in men with coronary artery disease and low cholesterol levels.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Dehydroepiandrosterone Sulfate; Drug Therapy, Combination; Ezetimibe; Follicle Stimulating Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Male; Middle Aged; Rosuvastatin Calcium; Sex Hormone-Binding Globulin; Simvastatin; Steroids; Testis; Testosterone | 2015 |
Statin Recapture Therapy before Coronary Artery Bypass Grafting Trial: Rationale and study design of a multicenter, randomized, double-blinded controlled clinical trial.
Topics: Cardiotonic Agents; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Postoperative Complications; Premedication; Simvastatin; Stroke; Treatment Outcome | 2015 |
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Niacin; Proportional Hazards Models; Simvastatin; Treatment Outcome; Triglycerides | 2016 |
[Evalation of Jingzhi Xiaoban Tablet in Improving Heart Function of Coronary Heart Disease Pa- tients by Doppler Tissue Imaging and Speckle Tracking Imaging Technology].
Topics: Coronary Artery Disease; Drugs, Chinese Herbal; Echocardiography, Doppler; Heart; Humans; Simvastatin; Tablets | 2016 |
Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Middle East; Prospective Studies; Simvastatin | 2008 |
Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Female; Germany; Humans; Male; Middle Aged; Prevalence; Risk Assessment; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
Topics: Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; CD40 Ligand; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Fibrinogen; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; P-Selectin; Platelet Aggregation; Simvastatin; Time Factors; Treatment Outcome | 2009 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Topics: Adult; Aged; Aged, 80 and over; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2009 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Humans; Indoles; Male; Metabolic Syndrome; Middle Aged; Simvastatin; Treatment Outcome | 2009 |
Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2009 |
Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease.
Topics: Aged; Azetidines; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Foot; Forearm; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Laser-Doppler Flowmetry; Lipids; Male; Microcirculation; Simvastatin; Skin; Ultrasonography | 2009 |
Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis.
Topics: Aged; Calcinosis; Coronary Angiography; Coronary Artery Disease; Female; Fibrosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Necrosis; Predictive Value of Tests; Pyrimidines; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional; User-Computer Interface | 2009 |
The SEAS Trial.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2010 |
[Effects of lipid-modulation and antiplatelet treatment on the endothelial lipase expression].
Topics: Adult; Aged; Blood Platelets; Coronary Artery Disease; Female; Humans; Hypolipidemic Agents; Lipase; Lipids; Male; Middle Aged; Simvastatin | 2010 |
Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Synergism; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Platelet Aggregation; Simvastatin | 2012 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study partici
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Simvastatin; Triglycerides | 2011 |
Long-term efficacy of pitavastatin versus simvastatin.
Topics: Aged; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Quinolines; Simvastatin | 2011 |
Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C-Reactive Protein; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Isoprostanes; Lipids; Male; Malondialdehyde; Metabolic Syndrome; Middle Aged; Oxidative Stress; Rosiglitazone; Simvastatin; Thiazolidinediones | 2012 |
Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arterial Occlusive Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Placebos; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Simvastatin | 2012 |
Statin treatment following coronary artery stenting and one-year survival.
Topics: Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pravastatin; Simvastatin; Stents; Survival Rate | 2002 |
Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease.
Topics: Biomarkers; C-Reactive Protein; Coronary Artery Disease; Diet; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Matrix Metalloproteinases; Middle Aged; Nitric Oxide; Prospective Studies; Simvastatin; Single-Blind Method; Tumor Necrosis Factor-alpha; Vasomotor System | 2002 |
Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Circadian Rhythm; Coronary Artery Disease; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides | 2002 |
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Topics: Atorvastatin; CD40 Ligand; Coronary Artery Disease; Double-Blind Method; Down-Regulation; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2003 |
Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL.
Topics: Antioxidants; Cholesterol; Constriction, Pathologic; Coronary Artery Disease; Desmosterol; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Niacin; Simvastatin; Sitosterols | 2003 |
Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Calcinosis; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Severity of Illness Index; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
Topics: Aged; Alberta; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Enalapril; Female; Humans; Male; Middle Aged; Quebec; Severity of Illness Index; Simvastatin; Treatment Outcome; Triglycerides | 2003 |
Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
Topics: Adult; Aged; Atorvastatin; Chemokines; Coronary Artery Disease; Dose-Response Relationship, Drug; Down-Regulation; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Male; Middle Aged; Pyrroles; Receptors, Chemokine; RNA, Messenger; Simvastatin; Time Factors | 2003 |
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Chemotherapy, Adjuvant; Coronary Artery Disease; Death, Sudden, Cardiac; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prospective Studies; Simvastatin | 2003 |
The effects of raloxifene and simvastatin on plasma lipids and endothelium.
Topics: Aged; Cell Adhesion Molecules; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Regional Blood Flow; Selective Estrogen Receptor Modulators; Simvastatin; Vascular Resistance | 2003 |
Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients with premature coronary sclerosis.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Area Under Curve; Biomarkers; Blood Pressure; Body Mass Index; Circadian Rhythm; Coronary Artery Disease; Dietary Fats; Dose-Response Relationship, Drug; Energy Intake; Fasting; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Netherlands; Predictive Value of Tests; Risk Factors; Sex Factors; Simvastatin; Treatment Outcome; Triglycerides | 2003 |
Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells.
Topics: Adult; Animals; Anticholesteremic Agents; Atorvastatin; Cell Differentiation; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Lovastatin; Male; Myocytes, Cardiac; Pyrroles; Rats; Simvastatin | 2004 |
Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).
Topics: Blood Glucose; Cholesterol, HDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Insulin; Liver; Male; Middle Aged; Muscle, Skeletal; Niacin; Simvastatin | 2004 |
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.
Topics: Angina Pectoris; Angina, Unstable; Atorvastatin; Coronary Artery Disease; Cross-Sectional Studies; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha | 2004 |
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Chronic Disease; Coronary Artery Disease; E-Selectin; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Nitric Oxide; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study.
Topics: Coronary Angiography; Coronary Artery Disease; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Simvastatin; Ultrasonography | 2004 |
A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Angiography; Coronary Artery Disease; Diet; Disease Progression; Female; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Odds Ratio; Prospective Studies; Simvastatin; Treatment Outcome | 2004 |
Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia.
Topics: Brachial Artery; Coronary Artery Disease; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Matrix Metalloproteinases; Middle Aged; Nitrates; Nitric Oxide; Simvastatin; Tissue Inhibitor of Metalloproteinase-1; Tumor Necrosis Factor-alpha; Vasodilation | 2004 |
Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Ramipril; Simvastatin; Vasomotor System | 2004 |
Reduction of myocardial ischemia with simvastatin in addition to conventional treatment in patients with chronic coronary artery disease.
Topics: Adult; Aged; Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Simvastatin | 2004 |
The effect of hormone replacement therapy and simvastatin on plasma homocysteine.
Topics: Aged; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Homocysteine; Humans; Hypercholesterolemia; Hypolipidemic Agents; Medroxyprogesterone; Middle Aged; Simvastatin; Time Factors; Treatment Outcome | 2005 |
Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound.
Topics: Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Male; Middle Aged; Premedication; Simvastatin; Stents; Ultrasonography, Interventional | 2005 |
Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease.
Topics: Aged; Coronary Artery Disease; Coronary Circulation; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microcirculation; Middle Aged; Positron-Emission Tomography; Pravastatin; Simvastatin; Time Factors; Ultrasonography | 2005 |
Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antithrombins; beta-Thromboglobulin; Blood Coagulation; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Fenofibrate; Fibrinolytic Agents; Humans; Hypercholesterolemia; Hypolipidemic Agents; Inflammation; Lipid Metabolism; Microscopy, Electron, Scanning; Platelet Activation; Simvastatin; Thrombin; Time Factors; Triglycerides | 2005 |
Impact of simvastatin therapy after heart transplantation an 11-year prospective evaluation.
Topics: Anticholesteremic Agents; Comorbidity; Coronary Artery Disease; Diet Therapy; Germany; Graft Rejection; Heart Transplantation; Humans; Longitudinal Studies; Prevalence; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Simvastatin; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cell Adhesion; Cells, Cultured; Chemokine CX3CL1; Chemokines, CX3C; Chemotaxis; Cholesterol, LDL; Coronary Artery Disease; CX3C Chemokine Receptor 1; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Leukocytes, Mononuclear; Membrane Proteins; Myocardial Infarction; Pyrroles; Receptors, Chemokine; Simvastatin; Umbilical Veins | 2005 |
Effect of simvastatin on coronary flow reserve in patients with atherosclerosis and hypercholesterolemia: an intracoronary Doppler study.
Topics: Blood Flow Velocity; Coronary Artery Disease; Coronary Vessels; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies; Simvastatin; Treatment Outcome; Ultrasonography, Doppler; Ultrasonography, Interventional | 2006 |
Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Fenofibrate; Fibrinolysis; Genotype; Heptanoic Acids; Humans; Male; Permeability; Pyrroles; Quinapril; Simvastatin; Tetrahydroisoquinolines; Thrombin; Thrombosis | 2006 |
Effect of simvastatin on coronary lesion site remodeling: a serial intravascular ultrasound study.
Topics: Aged; Anticholesteremic Agents; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Simvastatin; Treatment Outcome; Ultrasonography, Interventional | 2006 |
Different effects of simvastatin and losartan on cytokine levels in coronary artery disease.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Cytokines; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Simvastatin; Transforming Growth Factor beta; Treatment Outcome | 2006 |
[The effect of hypolipemic therapy with diet and simvastatin on the course of angina pectoris and the results of exercise stress test in patients with coronary artery disease].
Topics: Adult; Aged; Angina Pectoris; Coronary Artery Disease; Exercise Test; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2005 |
[Short Term Simvastatin Use in Patients With Systolic Heart Failure of Ischemic Origin Did Not Preclude Elevation of N-Terminal pro-Brain Natriuretic Peptide Level.].
Topics: Coronary Artery Disease; Heart Failure, Systolic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Natriuretic Peptide, Brain; Simvastatin | 2006 |
The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress.
Topics: Adult; Aged; Antibodies; Atorvastatin; Biomarkers; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipoproteins, LDL; Male; Middle Aged; Neopterin; Oxidative Stress; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
Low-density lipoprotein reduction by simvastatin is accompanied by angiotensin II type 1 receptor downregulation, reduced oxidative stress, and improved endothelial function in patients with stable coronary artery disease.
Topics: Cholesterol, LDL; Coronary Artery Disease; Down-Regulation; Endothelium, Vascular; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Oxidative Stress; Receptor, Angiotensin, Type 1; Simvastatin; Time Factors; Treatment Outcome | 2007 |
Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease.
Topics: Bone Density; Coronary Artery Disease; Double-Blind Method; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Osteoprotegerin; RANK Ligand; Simvastatin; Solubility | 2007 |
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atorvastatin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Circulation; Creatine Kinase; Dose-Response Relationship, Drug; E-Selectin; Enalapril; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Interleukin-6; Leukocyte Count; Male; Middle Aged; Platelet Count; Pyrroles; Ramipril; Simvastatin; Stroke Volume; Time Factors; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2007 |
The effect of simvastatin on erythrocyte membrane fluidity during oxidative stress induced by cardiopulmonary bypass: a randomized controlled study.
Topics: Aged; Cardiopulmonary Bypass; Cell Membrane Permeability; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Erythrocyte Deformability; Erythrocyte Membrane; Female; Hemolysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Membrane Fluidity; Middle Aged; Oxidative Stress; Postoperative Complications; Premedication; Simvastatin; Spectrometry, Fluorescence; Time Factors; Treatment Outcome | 2007 |
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS).
Topics: Aged; Anticholesteremic Agents; Calcium; Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Felodipine; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Research Design; Simvastatin; Tomography, X-Ray Computed | 1995 |
Validity of the 4S simvastatin trial.
Topics: Adult; Anticholesteremic Agents; Controlled Clinical Trials as Topic; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Synthase; Lovastatin; Middle Aged; Research Design; Simvastatin | 1995 |
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Lipids; Lovastatin; Male; Middle Aged; Myocardial Infarction; Simvastatin; Treatment Outcome | 1994 |
[Moderate hypercholesterolemia and coronary disease: the MAAS study and the 4S study].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Synthase; Hypercholesterolemia; Lovastatin; Middle Aged; Primary Prevention; Risk Factors; Simvastatin | 1995 |
Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
Topics: Adult; Blood Component Removal; Cholestyramine Resin; Colestipol; Coronary Angiography; Coronary Artery Disease; Data Interpretation, Statistical; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoprotein(a); Lipoproteins, LDL; Lovastatin; Middle Aged; Odds Ratio; Simvastatin | 1995 |
LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Component Removal; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Enzyme Inhibitors; Exercise Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin | 1996 |
Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).
Topics: Adult; Aged; Angiography, Digital Subtraction; Anticholesteremic Agents; Blood Component Removal; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin | 1996 |
Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Disease Progression; Enzyme Inhibitors; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Peripheral Vascular Diseases; Simvastatin | 1996 |
Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Cholesterol; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Enalapril; Female; Humans; Lovastatin; Male; Middle Aged; Research Design; Simvastatin; Treatment Outcome; Ventricular Function, Left | 1997 |
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Myocardial Revascularization; Niacin; Simvastatin; Treatment Outcome; Vitamins | 1998 |
Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis.
Topics: Adult; Aged; Angina Pectoris; Anticholesteremic Agents; Coronary Artery Disease; Coronary Circulation; Female; Hemodynamics; Humans; Lipids; Male; Middle Aged; Simvastatin; Time Factors; Tomography, Emission-Computed; Vasodilation | 1999 |
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.
Topics: Adult; Aged; Anticholesteremic Agents; Cause of Death; Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Neoplasms; Risk; Scandinavian and Nordic Countries; Simvastatin; Survival Rate | 2000 |
Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Blood Pressure; Cholesterol; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Enalapril; Female; Humans; Lipid Metabolism; Male; Middle Aged; Peptidyl-Dipeptidase A; Simvastatin; Treatment Outcome | 2000 |
Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin | 2001 |
Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Biomarkers; Chemokine CCL2; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Data Interpretation, Statistical; Endothelium, Vascular; Humans; Hypercholesterolemia; Matrix Metalloproteinase 9; Middle Aged; Simvastatin; Triglycerides; Tumor Necrosis Factor-alpha | 2001 |
Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease.
Topics: Aged; Anticholesteremic Agents; Coronary Artery Bypass; Coronary Artery Disease; Disease Progression; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Simvastatin | 2001 |
The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation.
Topics: Aged; Analysis of Variance; Blood Platelets; Chi-Square Distribution; Coronary Artery Disease; Coronary Thrombosis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Probability; Reference Values; Simvastatin; Treatment Outcome | 2002 |
Coronary atheroma regression trials. MAAS Steering Committee.
Topics: Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Worldwide experience with simvastatin/lovastatin.
Topics: Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Long-Term Care; Lovastatin; Rhabdomyolysis; Simvastatin | 1992 |
98 other study(ies) available for simvastatin and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Dead Meat: Glecaprevir/Pibrentasvir-Induced Statin Myonecrosis.
Topics: Antiviral Agents; Benzimidazoles; Biopsy; Coronary Artery Disease; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Male; Middle Aged; Myalgia; Pyrrolidines; Quinoxalines; Rhabdomyolysis; Simvastatin; Sulfonamides | 2020 |
Treatment Patterns of Lipid-Lowering Therapy in Patients with Coronary Artery Disease Aged Above and Below 75 Years: A Retrospective Cross-Sectional Study of 1500 Patients in a Tertiary Care Referral Center in Germany.
Topics: Age Factors; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Cross-Sectional Studies; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Simvastatin; Tertiary Care Centers; Tertiary Healthcare | 2020 |
Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Black People; Cardiomyopathy, Dilated; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Fatty Acids, Monounsaturated; Fluvastatin; Ghana; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Mortality; Multivariate Analysis; Probability; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2017 |
Role of simvastatin and RORα activity in the macrophage apoptotic pathway.
Topics: Apoptosis; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Nuclear Receptor Subfamily 1, Group F, Member 1; Simvastatin; THP-1 Cells | 2017 |
High- Versus Low-Dose Statin: Effects on Cardiovascular Events and All-Cause Death.
Topics: Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Quinolines; Simvastatin | 2018 |
Simvastatin reduces atherosclerotic plaques and endothelial inflammatory response in atherosclerosis rats through TGF-β/Smad pathway.
Topics: Animals; Anticholesteremic Agents; Aorta; Carotid Artery Diseases; Coronary Artery Disease; Interleukin-10; Interleukin-1beta; Interleukin-6; Lipids; Plaque, Atherosclerotic; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Interleukin-1; Simvastatin; Smad Proteins; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta | 2020 |
Simvastatin decreases stent-induced in-stent restenosis rate via downregulating the expression of PCNA and upregulating that of p27kip1.
Topics: Animals; Blotting, Western; Cell Cycle; Cell Proliferation; Coronary Artery Disease; Coronary Restenosis; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Down-Regulation; Immunohistochemistry; Immunosuppressive Agents; Male; Muscle, Smooth, Vascular; Proliferating Cell Nuclear Antigen; Rabbits; Random Allocation; Simvastatin; Stents; Up-Regulation | 2013 |
Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency.
Topics: Aged; Azetidines; Case-Control Studies; Coronary Artery Disease; Ezetimibe; Female; Follow-Up Studies; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hypolipidemic Agents; Lipids; Macromolecular Substances; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Randomized Controlled Trials as Topic; Risk Factors; Serine Endopeptidases; Simvastatin | 2014 |
Frequency and evolution of thin-capped fibroatheromas in left main coronary artery as assessed by serial virtual histology intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Phenotype; Plaque, Atherosclerotic; Pyrroles; Quinolines; Registries; Retrospective Studies; Simvastatin; Ultrasonography, Interventional | 2014 |
Effects of peroxisome proliferator-activated receptor γ in simvastatin antiplatelet activity: influences on cAMP and mitogen-activated protein kinases.
Topics: Anticholesteremic Agents; Blood Platelets; Coronary Artery Disease; Cyclic AMP; Humans; Mitogen-Activated Protein Kinases; Platelet Activation; Platelet Aggregation; PPAR gamma; Simvastatin | 2014 |
Low miR-19b-1-5p expression in isolated platelets after aspirin use is related to aspirin insensitivity.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Blood Platelets; Coronary Artery Disease; Drug Resistance; Humans; Indomethacin; Male; MicroRNAs; Middle Aged; Platelet Aggregation Inhibitors; RNA; Simvastatin | 2016 |
Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Prospective Studies; Registries; Risk Factors; Secondary Prevention; Simvastatin; Young Adult | 2016 |
Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect.
Topics: Adult; Aged; Aged, 80 and over; Antigen-Antibody Complex; Apolipoproteins B; Cholesterol, LDL; Coronary Artery Disease; Coronary Restenosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Male; Malondialdehyde; Middle Aged; Peripheral Arterial Disease; Simvastatin | 2016 |
Tobacco smoking, paraoxonase-1 (PON1) activity and pleiotropic effects of simvastatin treatment in patients with stable coronary artery disease (CAD).
Topics: Adult; Aged; Aryldialkylphosphatase; C-Reactive Protein; Coronary Artery Disease; Dinoprost; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Genetic; Simvastatin; Smoking; Tumor Necrosis Factor-alpha | 2015 |
Paraoxonase-1 activity and pleiotropic properties of simvastatin in obese and non-obese patients with stable coronary artery disease (CAD).
Topics: Adult; Aged; Aryldialkylphosphatase; C-Reactive Protein; Coronary Artery Disease; Dinoprost; Female; Humans; Male; Middle Aged; Obesity; Polymorphism, Single Nucleotide; Simvastatin; Tumor Necrosis Factor-alpha | 2016 |
Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality.
Topics: Adult; Atorvastatin; Cause of Death; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Netherlands; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin; Survival Rate; Treatment Outcome | 2016 |
Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines.
Topics: Aged; American Heart Association; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Guideline Adherence; Healthcare Disparities; Humans; Male; Medication Therapy Management; Middle Aged; Rosuvastatin Calcium; Simvastatin; United States; Veterans Health | 2016 |
Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Blood Platelets; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Rosuvastatin Calcium; Simvastatin; Vitamin D | 2017 |
[Dual lipid control without anti-atherosclerosis effect].
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Coronary Artery Disease; Disease Models, Animal; Endothelium, Vascular; Inflammation; Lipids; Male; Rabbits; Risk; Simvastatin; Stress, Mechanical; Tetrazoles; Valine; Valsartan | 2009 |
Uncertainty dogs Zetia and Vytorin.
Topics: Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Simvastatin; Uncertainty | 2008 |
The ENHANCE trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2008 |
The ENHANCE trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2008 |
Does 'ENHANCE' diminish confidence in ezetimibe?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Humans; Simvastatin | 2008 |
Native LDL-cholesterol mediated monocyte adhesion molecule overexpression is blocked by simvastatin.
Topics: Anticholesteremic Agents; CD11b Antigen; Cell Adhesion Molecules; Cholesterol, LDL; Coronary Artery Disease; Female; Humans; Hypercholesterolemia; L-Selectin; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Simvastatin | 2009 |
Can statins alter coronary plaque composition assessed by radiofrequency backscatter intravascular ultrasound?
Topics: Calcinosis; Coronary Artery Disease; Fatty Acids, Monounsaturated; Fibrosis; Fluorobenzenes; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Necrosis; Observer Variation; Predictive Value of Tests; Pyrimidines; Radiography; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Obesity as a risk factor for coronary events in Japanese patients with hypercholesterolemia on low-dose simvastatin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Body Mass Index; Cohort Studies; Coronary Artery Disease; Female; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Obesity; Risk Factors; Simvastatin | 2010 |
Mitochondrial dysfunction induced by statin contributes to endothelial dysfunction in patients with coronary artery disease.
Topics: Aged; Biomarkers; Brachial Artery; Coronary Artery Disease; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactic Acid; Male; Mitochondria, Heart; Mitochondrial Diseases; Pyruvic Acid; Regional Blood Flow; Simvastatin; Vasodilation | 2010 |
Gross proteinuria and subacute renal failure after coronary angiography - a case report of cholesterol crystal embolization.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Austria; Benzimidazoles; Biopsy; Biphenyl Compounds; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Disease Progression; Embolism, Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Malignant; Kidney; Male; Middle Aged; Proteinuria; Simvastatin; Tetrazoles | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cholesterol, HDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Proportional Hazards Models; Risk; Simvastatin; Triglycerides | 2010 |
[On the current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Effect of statin on the reference segments after bare-metal stent implantation.
Topics: Angioplasty, Balloon, Coronary; Coronary Artery Disease; Coronary Vessels; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metals; Simvastatin; Stents; Ultrasonography, Interventional | 2010 |
Usual dose of simvastatin does not inhibit plaque progression and lumen loss at the peri-stent reference segments after bare-metal stent implantation: a serial intravascular ultrasound analysis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metals; Middle Aged; Retrospective Studies; Simvastatin; Stents; Ultrasonography, Interventional | 2010 |
Altered fibrin clot properties in patients with retinal vein occlusion.
Topics: C-Reactive Protein; Coronary Artery Disease; Female; Fenofibrate; Fibrin; Fibrinolysis; Heptanoic Acids; Homocysteine; Humans; Hypersensitivity, Immediate; Laser Coagulation; Lipoprotein(a); Male; Pyrroles; Retinal Vein; Retinal Vein Occlusion; Simvastatin; Tetrahydroisoquinolines; Thrombosis; Venous Thromboembolism; Venous Thrombosis | 2011 |
Trial clouds use of niacin with a statin.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Simvastatin; Treatment Failure | 2011 |
Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Substitution; Drugs, Generic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Medication Adherence; Simvastatin; Triglycerides | 2011 |
Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin.
Topics: Coronary Artery Disease; Fatal Outcome; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Cirrhosis; Male; Middle Aged; Rhabdomyolysis; Simvastatin | 2011 |
Effect of statins on coronary bifurcation atherosclerosis: an intravascular ultrasound virtual histology study.
Topics: Aged; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Fibrosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Necrosis; Odds Ratio; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Calcification | 2012 |
Déjà vu all over again.
Topics: Arterial Occlusive Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Humans; Male; Simvastatin | 2012 |
Letter by Kuller and Mackey regarding article, "Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection study".
Topics: Arterial Occlusive Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Humans; Male; Simvastatin | 2012 |
Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Cerebrovascular Disorders; Coronary Artery Disease; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peripheral Vascular Diseases; Pyrroles; Secondary Prevention; Simvastatin | 2012 |
Preparation and in vitro percutaneous penetration of simvastatin ethosome gel.
Topics: Administration, Cutaneous; Animals; Coronary Artery Disease; Drug Delivery Systems; Gels; Humans; In Vitro Techniques; Male; Mice; Mice, Inbred Strains; Simvastatin; Skin; Unilamellar Liposomes | 2013 |
LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects.
Topics: Aged; Anticholesteremic Agents; Bile Acids and Salts; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Artery Disease; Diet, Fat-Restricted; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Intestinal Absorption; Male; Simvastatin; Sitosterols; Treatment Outcome | 2002 |
Getting more people on statins.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Simvastatin; United States | 2002 |
Comparison of effectiveness and safety of simvastatin in patients <75 versus > or =75 years of age with coronary, cerebral, or peripheral arterial disease.
Topics: Age Factors; Aged; Cerebral Arterial Diseases; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Peripheral Vascular Diseases; Retrospective Studies; Risk Factors; Safety; Simvastatin; Survival Analysis; Treatment Outcome | 2002 |
[Clinical study of the month. The MRC/BHF Heart Protection Study].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Coronary Artery Disease; Diabetes Complications; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Sex Factors; Simvastatin; Stroke; Survival Analysis; Treatment Outcome | 2002 |
[One more (conclusive?) confirmation of ineffectiveness of antioxidant vitamins for prevention of coronary heart disease].
Topics: Anticholesteremic Agents; Antioxidants; Clinical Trials as Topic; Coronary Artery Disease; Humans; Simvastatin; Treatment Failure | 2002 |
Effect of statin therapy on total mortality. Trial in a more varied population.
Topics: Antioxidants; Coronary Artery Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Mortality; Placebos; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
Current perspectives on statins.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Coronary Artery Disease; Female; Humans; India; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Effect of statins on the progression of bioprosthetic aortic valve degeneration.
Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atorvastatin; Bioprosthesis; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Prosthesis Failure; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome; Ultrasonography | 2003 |
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Artery Disease; Coronary Disease; Diabetes Mellitus; Female; Humans; Incidence; Male; Metabolic Syndrome; Middle Aged; Placebos; Prevalence; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Simvastatin; Triglycerides | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Improvement in the function of hibernating myocardium in a patient with heart failure due to coronary artery disease receiving high-dose simvastatin.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Myocardial Contraction; Myocardial Stunning; Simvastatin; Stroke Volume; Ventricular Dysfunction, Left | 2004 |
Regression of coronary in-stent restenosis.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Blood Vessel Prosthesis Implantation; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Humans; Hypercholesterolemia; Male; Simvastatin; Stents; Ultrasonography, Interventional | 2004 |
Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies.
Topics: Asia; Clinical Trials as Topic; Coronary Artery Disease; Humans; Hypolipidemic Agents; Middle Aged; Simvastatin; Treatment Outcome | 2004 |
Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting.
Topics: Aged; Atorvastatin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Pyrroles; Simvastatin; Stents; Ticlopidine | 2004 |
Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis.
Topics: Apolipoproteins; Carrier Proteins; Cholesterol Ester Transfer Proteins; Chylomicron Remnants; Chylomicrons; Coronary Artery Disease; Dose-Response Relationship, Drug; Fasting; Female; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Postprandial Period; Simvastatin; Triglycerides | 2005 |
[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Cost Control; Drug Costs; Ezetimibe; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrroles; Simvastatin | 2004 |
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine | 2004 |
Prevention of coronary atherosclerosis by the use of combination therapy with antioxidant coenzyme Q10 and statins.
Topics: Antioxidants; Coenzymes; Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Nitric Oxide; Oxidative Stress; Platelet Aggregation; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Ubiquinone | 2005 |
Plaque regression--a new target for antiatherosclerotic therapy.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Premedication; Pyrroles; Radiography; Remission Induction; Risk Reduction Behavior; Simvastatin; Ultrasonography | 2005 |
Targeting healthcare disparities: an integrated model to improve treatment rates of dyslipidemia in African American patients.
Topics: Alcohol Drinking; Ambulatory Care; Atherosclerosis; Black People; Cholesterol, LDL; Clinical Protocols; Coronary Artery Disease; Curriculum; Diabetes Mellitus; Diet; Dyslipidemias; Female; Georgia; Humans; Hypolipidemic Agents; Internal Medicine; Internship and Residency; Male; Middle Aged; Patient Education as Topic; Risk Factors; Simvastatin; Smoking | 2005 |
Protective effects of simvastatin on coronary artery function in swine with acute infection.
Topics: Acetylcholine; Acute Disease; Animals; Bradykinin; Chlamydophila Infections; Chlamydophila pneumoniae; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Simvastatin; Swine | 2006 |
HMG-CoA reductase inhibitors improve acute ischemic stroke outcome.
Topics: Brain Ischemia; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Simvastatin; Stroke; Treatment Outcome | 2005 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
Effect of 80 mg/day simvastatin therapy on cardiovascular outcomes in adults with versus without metabolic syndrome.
Topics: Adult; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indiana; Male; Metabolic Syndrome; Middle Aged; Retrospective Studies; Simvastatin; Treatment Outcome | 2006 |
Usefulness of follow-up low-density lipoprotein cholesterol level as an independent predictor of changes of coronary atherosclerotic plaque size as determined by intravascular ultrasound analysis after statin (atorvastatin or simvastatin) therapy.
Topics: Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Databases as Topic; Elastic Tissue; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Pyrroles; Simvastatin; Tunica Media; Ultrasonography, Interventional | 2006 |
Arterial stiffness and Chlamydia pneumoniae infection in coronary artery disease. Is there a link?
Topics: Adult; Aged; Arteries; Atorvastatin; Chlamydia Infections; Chlamydophila pneumoniae; Constriction, Pathologic; Coronary Artery Disease; Diabetes Mellitus; Double-Blind Method; Female; Heptanoic Acids; Humans; Immunoglobulin A; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Smoking; Vascular Resistance | 2006 |
[Combination treatment with coenzyme Q10 and simvastatin in patients with coronary atherosclerosis].
Topics: Adult; Aged; Antioxidants; Coenzymes; Coronary Angiography; Coronary Artery Disease; Cytoprotection; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxides; Male; Middle Aged; Nitric Oxide; Oxidative Stress; Simvastatin; Treatment Outcome; Ubiquinone | 2006 |
Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Resistance; Female; Heptanoic Acids; Heterozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Retrospective Studies; Risk Factors; Scavenger Receptors, Class E; Simvastatin; Thrombosis | 2007 |
Hypercholesterolaemia impairs monocyte function in CAD patients.
Topics: Aged; Anticholesteremic Agents; Case-Control Studies; Chemokine CCL2; Chemotaxis; Cholesterol, LDL; Collateral Circulation; Coronary Artery Disease; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Monocytes; Simvastatin; Statistics, Nonparametric; Vascular Endothelial Growth Factor A | 2007 |
The level of hs-CRP in coronary artery ectasia and its response to statin and angiotensin-converting enzyme inhibitor treatment.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Dilatation, Pathologic; Female; Humans; Immunoassay; Male; Middle Aged; Prognosis; Simvastatin; Treatment Outcome | 2007 |
Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
Topics: Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; Treatment Outcome | 2007 |
Unrecognized confounders in overcoming clinical inertia study.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Confounding Factors, Epidemiologic; Coronary Artery Disease; Diabetes Mellitus; Education, Continuing; Health Personnel; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Risk Assessment; Simvastatin | 2008 |
Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase.
Topics: Adult; Cells, Cultured; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Endothelial Cells; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type III; RNA, Messenger; Simvastatin; Umbilical Veins; Vasodilation | 2009 |
Direct effect of statins on homocysteine-induced endothelial adhesiveness: potential impact to human atherosclerosis.
Topics: Aged; Anticholesteremic Agents; Case-Control Studies; Cell Adhesion; Cell Adhesion Molecules; Coronary Artery Disease; Endothelial Cells; Endothelium, Vascular; Female; Homocysteine; Humans; Male; Middle Aged; Pravastatin; Simvastatin | 2008 |
High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins.
Topics: Aged; Atorvastatin; Case-Control Studies; Cells, Cultured; Chemokine CCL2; Chemokine CXCL16; Chemokines, CXC; Coronary Artery Disease; Down-Regulation; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Muscle, Smooth, Vascular; Pyrroles; Receptors, Scavenger; Simvastatin | 2008 |
Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up.
Topics: Anticholesteremic Agents; Coronary Artery Disease; Dyslipidemias; Female; Follow-Up Studies; Gene Expression; Humans; Longitudinal Studies; Male; Middle Aged; Neutrophils; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Simvastatin; Up-Regulation | 2008 |
Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Disease; Death, Sudden, Cardiac; Humans; Lovastatin; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence; Scandinavian and Nordic Countries; Simvastatin; Survival Analysis | 1996 |
Suppressive effect of simvastatin on intramural small coronary arterial lesions in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cholesterol, Dietary; Coronary Artery Disease; Coronary Vessels; Depression, Chemical; Diet, Atherogenic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Linear Models; Male; Rabbits; Random Allocation; Simvastatin | 1998 |
Cardiovascular risk in hypertension: implications of the Sheffield Table for lipid-lowering strategy.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Humans; Hypertension; Prospective Studies; Risk Factors; Simvastatin; Treatment Outcome | 1998 |
[Improved coronary vasodilator capacity by drug lipid lowering therapy in patients in the early stage of coronary atherosclerosis with reduced coronary reserves and moderate LDL hypercholesteremia].
Topics: Adult; Aged; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Diet, Fat-Restricted; Dipyridamole; Exercise Test; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Treatment Outcome; Vasodilation | 1998 |
Coronary artery reactivity after treatment with simvastatin.
Topics: Amlodipine; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Female; Humans; Male; Myocardial Infarction; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Simvastatin; Survival Rate; Treatment Outcome | 2001 |
HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
Topics: Antioxidants; Cell Movement; Cells, Cultured; Coronary Artery Disease; Coronary Vessels; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoenzymes; Lysophosphatidylcholines; Mevalonic Acid; Muscle, Smooth, Vascular; Oligonucleotides, Antisense; Oxidative Stress; Phospholipase D; Pravastatin; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Protein-Tyrosine Kinases; Simvastatin | 2001 |
Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin.
Topics: Apolipoproteins B; Area Under Curve; Complement C3; Coronary Artery Disease; Fasting; Female; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Postprandial Period; Simvastatin; Triglycerides | 2001 |
Antioxidants blunt high-density lipoprotein response to statin plus niacin therapy.
Topics: Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Niacin; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Body Mass Index; Coronary Artery Disease; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Japan; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prevalence; Simvastatin; Triglycerides | 2002 |
Niacin-simvastatin combination benefits patients with coronary artery disease.
Topics: Antioxidants; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Niacin; Simvastatin | 2001 |
The use over time of statins in coronary patients in an Italian tertiary referral center.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Utilization Review; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2001 |
[Statin treatment of cardiac risk patients means: 1. Far more patients benefit, 2. Initial LDL doesn't matter].
Topics: Aged; Cholesterol, LDL; Coronary Artery Disease; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2001 |
Racial differences in compliance with NCEP-II recommendations for secondary prevention at a Veterans Affairs medical center.
Topics: Adult; Aged; Black or African American; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Guideline Adherence; Hospitals, Veterans; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Practice Guidelines as Topic; Probability; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin; United States; White People | 2002 |
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
Topics: Acute Disease; Cholesterol; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Pravastatin; Proportional Hazards Models; Risk Factors; Simvastatin; Substance Withdrawal Syndrome; Survival Rate; Treatment Outcome; Troponin; United States | 2002 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2002 |
The effects of simvastatin-niacin and antioxidant therapy on HDL.
Topics: Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Niacin; Simvastatin; Treatment Outcome | 2002 |
Statin therapy: beyond cholesterol lowering and antiinflammatory effects.
Topics: Animals; Anti-Inflammatory Agents; Carotid Stenosis; Cell Movement; Coronary Artery Disease; Endothelium, Vascular; Hematopoietic Stem Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Rats; Simvastatin | 2002 |
[Preventive effect of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis in cholesterol-fed rabbits].
Topics: Animals; Anticholesteremic Agents; Cholesterol, Dietary; Coronary Artery Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Rabbits; Simvastatin | 1991 |
Effects of therapy with diet and simvastatin on atherosclerosis in hypercholesterolemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |